EDGAR·FLOW

Rein Therapeutics, Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Rein Therapeutics announced preliminary blinded interim data from its Phase 2 RENEW trial of LTI-03 in idiopathic pulmonary fibrosis: 33% of 24 evaluable patients (8 patients) showed FVC improvement at Week 12; 46% (11 patients) experienced FVC decline ≤5.7%; no serious adverse events attributed to treatment; 92% of enrolled participants remained on study. Trial is 75% enrolled (90 of ~120 patients) and on track to report topline data in 2027. Cash position of $36.5M is expected to fund operations into Q1 2028.
Why this rating

Early-stage biotech with single lead program; encouraging interim safety/lung function trends support Phase 2 progression. Runway to data readout de-risks near-term. Data is blinded, pooled, and not comparative—modest predictive power. Meaningful for company trajectory but not transformational yet.

Tradability signal
NO TRADE

No trade: price $0.30 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$0.56 ▲ 54.68%
at our read · unknown
$0.36
+10 min · unknown
$0.30 ▼ 16.81%
+30 min · unknown
$0.40 ▲ 10.98%
+1 hr · unknown
$0.43 ▲ 21.13%
+4 hrs · unknown
$0.41 ▲ 14.27%

The stock had already moved -35.35% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ RNTX · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.